SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
BMY reported Third Quarter 2026 results. The stock moved +1.4% on the print.
BMYearnings

Earnings reactions, page 9

Bristol-Myers Squibb Company (BMY) Q3 FY2026 earnings

October 29, 2026 · SharpeIQ Research Desk

Reported results

  • Total revenues increased 7% to $13.1 billion.
  • Growth Portfolio revenues increased 12% to $7.7 billion.
  • GAAP EPS was $1.05 and non-GAAP EPS was $1.35.
  • Legacy Portfolio revenues of $5.4 billion increased 1%.
  • U.S. revenues of $9.1 billion increased 9%.
  • International revenues of $4.0 billion increased 3%.

Guidance

  • Full-year 2026 revenue guidance range of $49.75 billion to $50.25 billion.
  • Full-year 2026 non-GAAP EPS range of $6.35 to $6.55.
  • Full-year 2026 other income/(expense) expected to be ~$650 million of expense.
  • 2026 Worldwide Eliquis revenue growth guidance of 20% - 25%.

Price and volatility reaction

The stock moved +1.4% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -4.3 vol points across the event (constant-maturity series — not the front-week crush).

MeasureValueBasis
Close before release60.572026-10-28
Close after release61.392026-10-29
Realised move+1.4%close to close
30d ATM IV change-4.3 vol ptsconstant-maturity series, not the front expiry
Price and volatility reaction. Closes either side of the release. No front-expiry chain on file for a straddle expected move. SharpeIQ — listed option chain and price_history

Source

The figures above come from the earnings release the company filed with the SEC on 2026-10-29 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →